Diligence memo · auto-generated · as of July 3, 2026
OncoRock Therapeutics Inc.
OncoRock Therapeutics Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
OncoRock Therapeutics Inc. operates in Pharma, based in LITTLE ROCK.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
OncoRock Therapeutics Inc. has raised $125K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $125K on 2025-10-14.
Most recent recorded round closed around 2025-10-14.
Valuation (modeled)modeled
Provath models OncoRock Therapeutics Inc. at approximately $266K (range $70K–$606K). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.42× the median modeled value of Pre-Seed Pharma companies in 2025–2027 (8 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 9 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 19% of Pharma peers (310 compared).
Modeled value ranks above 17% of those peers.
Closest niche peers: Mizar Therapeutics, Inc., ReEngage Therapeutics, Inc., King Therapeutics LLC, Dnp Therapeutics Inc, Protibea Therapeutics, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.